Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  HIV Infection

  Free Subscription


2 AIDS Res Hum Retroviruses
4 Clin Infect Dis
1 J Immunol
1 J Med Virol
1 Lancet
2 Lancet Infect Dis
1 N Engl J Med
1 Nature
1 PLoS Med
3 PLoS One
1 PLoS Pathog
1 Proc Natl Acad Sci U S A
2 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. SINGH K, Natarajan V, Dewar R, Rupert A, et al
    Long-term persistence of transcriptionally-active "defective" HIV-1 proviruses: Implications for persistent immune activation during antiretroviral therapy.
    AIDS. 2023 Aug 8. doi: 10.1097/QAD.0000000000003667.
    PubMed         Abstract available

    AIDS Res Hum Retroviruses

  2. LANZAFAME M, Lattuada E, Luise D, Delama A, et al
    AIDS Res Hum Retroviruses. 2023 Aug 8. doi: 10.1089/AID.2022.0168.
    PubMed         Abstract available

  3. MARQUIS KA, Merenstein C, Bushman F
    2-hydroxyisovalerate is produced during bacterial vaginosis and boosts HIV infection in resting T cells.
    AIDS Res Hum Retroviruses. 2023 Aug 7. doi: 10.1089/AID.2022.0171.
    PubMed         Abstract available

    Clin Infect Dis

  4. ZHUANG Y, Wang M, Liang L, Mao Y, et al
    The first known human death after infection with the avian influenza (A/H3N8) virus: Guangdong Province, China, March 2023.
    Clin Infect Dis. 2023 Aug 9:ciad462. doi: 10.1093.
    PubMed         Abstract available

  5. SACK DE, Brantley M, Ratliff M, Mathieson S, et al
    Misclassification of Loss to Care Among Persons with HIV: Improved Capture of Silent Transfers through Surveillance Linkage using Statewide Mandatorily Reported Laboratory Measures.
    Clin Infect Dis. 2023 Aug 9:ciad461. doi: 10.1093.
    PubMed         Abstract available

  6. SCHOMAKER M, Kerschberger B, Boulle A
    Response to "Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus (HIV) Treatment-How to Interpret Discrepancies Between Different Studies".
    Clin Infect Dis. 2023 Aug 5:ciad459. doi: 10.1093.

  7. BROUGH J, Martinez L, Hatherill M, Zar HJ, et al
    Public health impact and cost-effectiveness of screening for active tuberculosis disease or infection among children in South Africa.
    Clin Infect Dis. 2023 Aug 5:ciad449. doi: 10.1093.
    PubMed         Abstract available

    J Immunol

  8. SANDBERG JK, Leeansyah E, Eller MA, Shacklett BL, et al
    The Emerging Role of MAIT Cell Responses in Viral Infections.
    J Immunol. 2023;211:511-517.
    PubMed         Abstract available

    J Med Virol

  9. GIOVANETTI M, Branda F, Cella E, Scarpa F, et al
    Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2.
    J Med Virol. 2023;95:e29012.
    PubMed         Abstract available


  10. Cause-specific mortality by county, race, and ethnicity in the USA, 2000-19: a systematic analysis of health disparities.
    Lancet. 2023 Aug 3:S0140-6736(23)01088-7. doi: 10.1016/S0140-6736(23)01088.
    PubMed         Abstract available

    Lancet Infect Dis

  11. OUK V, Pham CD, Wi T, van Hal SJ, et al
    The Enhanced Gonococcal Surveillance Programme, Cambodia.
    Lancet Infect Dis. 2023 Aug 4:S1473-3099(23)00479.

  12. HERRERA K, Lyang J, Holly T, Faherty EA, et al
    Extragenital gonorrhoea, chlamydia, and HIV co-infection in people with mpox.
    Lancet Infect Dis. 2023 Aug 4:S1473-3099(23)00483.

    N Engl J Med

  13. KRAKOWER D, Marcus JL
    Free the PrEP - Over-the-Counter Access to HIV Preexposure Prophylaxis.
    N Engl J Med. 2023 Aug 5. doi: 10.1056/NEJMp2305644.


  14. ZHAO Y, Lu Y, Richardson S, Sreekumar M, et al
    TRIM5alpha restricts poxviruses and is antagonized by CypA and the viral protein C6.
    Nature. 2023 Aug 9. doi: 10.1038/s41586-023-06401.
    PubMed         Abstract available

    PLoS Med

  15. DOVEL K, Balakasi K, Phiri K, Shaba F, et al
    Effect of index HIV self-testing for sexual partners of clients enrolled in antiretroviral therapy (ART) programs in Malawi: A randomized controlled trial.
    PLoS Med. 2023;20:e1004270.
    PubMed         Abstract available

    PLoS One

  16. SQUILLACE N, Ricci E, Maggi P, Taramasso L, et al
    Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
    PLoS One. 2023;18:e0289132.
    PubMed         Abstract available

  17. MALECHE-OBIMBO E, Attia E, Were F, Jaoko W, et al
    Prevalence, clinical presentation and factors associated with chronic lung disease among children and adolescents living with HIV in Kenya.
    PLoS One. 2023;18:e0289756.
    PubMed         Abstract available

  18. MCCLYMONT E, Bone J, Orem J, Okuku F, et al
    Increased frequency and quantity of mucosal and plasma cytomegalovirus replication among Ugandan Adults Living with HIV.
    PLoS One. 2023;18:e0287516.
    PubMed         Abstract available

    PLoS Pathog

  19. TONG T, D'Addabbo A, Xu J, Chawla H, et al
    Impact of stabilizing mutations on the antigenic profile and glycosylation of membrane-expressed HIV-1 envelope glycoprotein.
    PLoS Pathog. 2023;19:e1011452.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  20. WANG Z, Petricca J, Liu M, Zhang S, et al
    SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Proc Natl Acad Sci U S A. 2023;120:e2220472120.
    PubMed         Abstract available


  21. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  22. IZULLA P, Wagai JN, Akelo V, Ombeva A, et al
    Vaccine safety surveillance in Kenya using GAIA standards: A feasibility assessment of existing national and subnational research and program systems.
    Vaccine. 2023 Aug 5:S0264-410X(23)00906-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.